| Name | Title | Contact Details |
|---|
eb5 Corporation is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Quality Home Health Care is a Sanford, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Well Point is a Half Moon Bay, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aurora Spine Corporation focuses on the development and distribution of spinal implant products for relieving back pain, and preserving spinal bone structure and anatomy in the United States. The company intends to provide interspinous process lumbar fusion devices for patients suffering from degenerative disc disease whose pain has not been eliminated by non-surgical treatment methods; polyether ether ketone interbody cages for use in spinal fusion procedures; and cervical and lumbar devices. It also plans to develop installation tools for surgeons. The company was incorporated in 2013 and is headquartered in Toronto, Canada.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.